I-MAB (IMAB) has released an update.
I-Mab, a NASDAQ-listed biopharmaceutical company, is making strides in the development of innovative cancer therapies with a robust pipeline, including uliledlimab, givastomig, and ragistomig, targeting various cancers. The company boasts a strong financial position with a cash balance of $321.8 million as of the end of 2023, further solidified by the divestiture of its China operations. Positioned for significant value creation, I-Mab is advancing its portfolio with key milestones anticipated in 2024.
For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.
